IL-6: Relevance for immunopathology of SARS-CoV-2

Area of Science:

• * Immunology and Virology
• * Infectious Diseases and Critical Care Medicine

Background:

• * COVID-19 severity ranges from mild symptoms to critical illness, including severe pneumonia, acute respiratory distress syndrome (ARDS), cytokine release syndrome (CRS), and multiorgan failure.
• * Early identification of patients at high risk for adverse outcomes is crucial for timely intervention.
• * Elevated systemic interleukin-6 (IL-6) levels are associated with severe COVID-19 and increased need for intensive care.

Purpose of the Study:

• * To review the mechanisms by which IL-6 contributes to COVID-19 exacerbation.
• * To explore the potential of anti-IL-6 biologic therapies for managing severe COVID-19.

Main Methods:

• * Literature review of studies investigating IL-6 in COVID-19 pathogenesis.
• * Analysis of proposed mechanisms linking IL-6 to severe disease manifestations.
• * Evaluation of clinical data and preclinical studies on anti-IL-6 agents.

Main Results:

• * IL-6 plays a significant role in the inflammatory cascade leading to ARDS and CRS in COVID-19.
• * High IL-6 levels correlate strongly with disease severity, ICU admission, and mortality.
• * Targeting IL-6 pathways has shown promise in preclinical and early clinical studies.

Conclusions:

• * Interleukin-6 is a key mediator in severe COVID-19, driving critical complications.
• * Monitoring IL-6 levels can aid in risk stratification and patient management.
• * Anti-IL-6 biologics represent a promising therapeutic strategy for severe COVID-19 patients.